The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes

reposted from

The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes

The problem with this study is the use of the B-SIT which is far more restricted than the UPSIT (12 items versus 40). Previous studies have shown comparable diagnostic accuracy between UPSIT and DaTSCAN, although one might perhaps expect imaging to perform better than objective smell testing. One needs to consider the costs here... UPSIT $25 and DaTSCAN over $1000. In my opinion both have a place in the clinical and research setting, and agree that in combination predictive value is likely to maximal...

J Neurol. 2015 Jun 30. [Epub ahead of print]

Georgiopoulos C, Davidsson A, Engström M, Larsson EM, Zachrisson H, Dizdar N.

Abstract

The aim of the study was to compare the efficacy of olfactory testing and presynaptic dopamine imaging in diagnosing Parkinson's disease (PD) and atypical parkinsonian syndromes (APS); to evaluate if the combination of these two diagnostic tools can improve their diagnostic value. A prospective investigation of 24 PD patients, 16 APS patients and 15 patients with non-parkinsonian syndromes was performed during an 18-month period. Single photon emission computed tomography with the presynaptic radioligand 123I-FP-CIT (DaTSCAN®) and olfactory testing with the Brief 12-item Smell Identification Test (B-SIT) were performed in all patients. DaTSCAN was analysed semi-quantitatively, by calculating two different striatal uptake ratios, and visually according to a predefined ranking scale. B-SIT score was significantly lower for PD patients, but not significantly different between APS and non-parkinsonism. The visual assessment of DaTSCAN had higher sensitivity, specificity and diagnostic accuracy compared to olfactory testing. Most PD patients (75 %) had visually predominant dopamine depletion in putamen, while most APS patients (56 %) had visually severe dopamine depletion both in putamen and in caudate nucleus. The combination of DaTSCAN and B-SIT led to a higher rate of correctly classified patients. Olfactory testing can distinguish PD from non-parkinsonism, but not PD from APS or APS from non-parkinsonism. DaTSCAN is more efficient than olfactory testing and can be valuable in differentiating PD from APS. However, combining olfactory testing and DaTSCAN imaging has a higher predictive value than these two methods separately.

Eyes, Nose as Windows to Alzheimer’s

reposted from

Eyes, Nose as Windows to Alzheimer’s

Failing a sniff test or screening positive on an eye exam may predict people’s chances of developing the neurodegenerative disorder.

By Kerry Grens | July 14, 2014

• Comment
• Print

• Link this
• Stumble
• Tweet this

WIKIMEDIA, ADAMANTIOSA suite of studies presented at the ongoing Alzheimer's Association International Conference in Copenhagen offers a variety of ways to diagnose the neurodegenerative disease at early stages. In some cases, researchers worked out the chances of developing the disease among people who can’t smell certain odors, and in other studies scientists tested the utility of Alzheimer’s biomarkers in the eye.

“We envision a future where we can predict risk and then do things to lower risk,” Matthew Growdon, a medical student at Harvard Medical School and the Harvard School of Public Health who is working on a such a smell test, told theWashington Post.

Alzheimer’s sniff tests have been proposed before. The idea is that a poorer performance for odor detection could predict cognitive decline. “A loss of sense of smell does not mean you have Alzheimer's disease,” Kenneth Heilman, a professor in the department of neurology at the University of Florida College of Medicine in Gainesville, told HealthDay. “But if someone has episodic memory loss and also has a loss of smell, a degenerative disease like Parkinson’s or Alzheimer’s is a possibility.”

Just north of the nose, the eyes may also be windows into one’s cognitive state. Researchers reported at the conference two methods to detect beta amyloid protein using fluorescent tags either in the lens or the retina of the eye. According to The Guardian, “both tests showed that levels of beta-amyloid in the eye mirrored those seen in the brain by PET [positron emission tomography] imaging.”

Shaun Frost from Australia’s Commonwealth Scientific and Industrial Research Organisation who led one of the eye biomarker studies, told the Guardian, “if further research shows that our initial findings are correct, it could potentially be delivered as part of an individual's regular eye check-up. The high resolution level of our images could also allow accurate monitoring of individual retinal plaques as a possible method to follow progression and response to therapy.”

Such tests are not likely to be perfectly accurate, USA Today pointed out, but they may help determine who needs more definitive—and costly—testing. “Everyone with Alzheimer’s has beta amyloid in their brain, but not everyone with beta amyloid buildup will develop Alzheimer’s, limiting the predictive ability of some of these tests.”

Tags

smell, olfaction, diagnostics, biomarkers, amyloid and Alzheimer's Disease

reposted from here

Public release date: 23-Sep-2013
[ Print | E-mail |  Share

 ] [ Close Window ] 

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology 

2-item questionnaire proves to be a valid depression screening tool for radiation therapy patients

Atlanta, September 23, 2013 — Cancer patients receiving radiotherapy (RT) who are potentially suffering from depression can be effectively identified by a two-item questionnaire, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

The Radiation Oncology Therapy Group (RTOG) Community Clinical Oncology Program (CCOP)-supported multi-institutional study screened 455 patients receiving radiation treatment at 37 centers around the U.S. Participants in the study were seeking treatment for breast cancer (45 percent); GI cancer (11 percent); lung cancer (10 percent); gynecologic cancer (6 percent); or other cancers (27 percent). Sixty-six percent of the patients in the trial (298) were women.

Depression screenings were performed before or within two weeks of treatment of the initial cancer diagnosis. The screening forms included the single-item National Comprehensive Cancer Network-Distress Thermometer (NCCN-DT); the Hopkins Symptom Checklist (HSCL-25);and the nine-item Patient Health Questionnaire, (PHQ-9), which includes Patient Health Questionnaire-2 (PHQ-2) as its first two questions. All of the study participants answered the screening questionnaires with 100 percent completion.

Patients received the PHQ-9 and were asked if, within the past two weeks, they had "little interest or pleasure in doing things," or "if they were feeling down, depressed or hopeless." It was discovered that patients' responses to these two questions (the PHQ-2) were as useful in identifying depression as results from the entire PHQ-9, and were more indicative than results from the NCCN-DT.

Within the study, a total of 75 patients (16 percent) screened positively for depressive symptoms. PHQ-9 and PHQ-2 had similar accuracy in detecting depression with an area under the curve (AUC) of approximately 0.83 for each and was superior to the HLSC-25 (.79) and the NCCN-DT (.60).

Of the facilities included in the study, 68 percent offer mental health services. Patients who screened positive for depression symptoms, along with a systematic sample of patients who screened negative, were administered the Structured Clinical Interview for DSM-IV (SCID) Mood Disorder modules by telephone. The study determined that screening in an RT setting was well-received by patients and feasible.

"Detection of depression in cancer patients is an important public health priority, and the ability to screen and treat cancer patients for depression can have a major impact on a patient's quality of life," said William Small Jr., MD, FASTRO, presenting author of the study and chairman of the Department of Radiation Oncology at Loyola University Chicago. "This study was designed to test the feasibility of screening for major depression in cancer patients receiving radiation therapy. The ability of a two-question survey to effectively screen for depression will hopefully prompt more centers to screen and to refer patients in need of mental health services," said Lynn I. Wagner, PhD, principal investigator of the study and an associate professor in the Department of Psychiatry and Behavioral Sciences at the Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago.

###

The abstract, "RTOG 0841: Two Item Questionnaire Effectively Screens for Depression in Cancer Patients Receiving Radiotherapy," will be presented at ASTRO's Annual Meeting in the Plenary session at 2:00 p.m. Eastern time on Monday, September 23, 2013. To speak with Dr. Small or Dr. Wagner, contact Michelle Kirkwood on September 22 – 25, 2013, in the ASTRO Press Office at the Georgia World Congress Center in Atlanta at 404-222-5303 or 404-222-5304, or email michellek@astro.org.

ASTRO's 55th Annual Meeting, held in Atlanta, September 22-25, 2013, is the premier scientific meeting in radiation oncology and brings together more than 11,000 attendees including oncologists from all disciplines, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants, practice administrators, industry representatives and other health care professionals from around the world. The theme of the 2013 meeting is "Patients: Hope • Guide • Heal" and focuses on patient-centered care and the importance of the physician's role in improving patient-reported outcomes and the quality and safety of patient care. The four-day scientific meeting includes presentation of four plenary papers, 363 oral presentations, 1,460 posters and 144 digital posters in 70 educational sessions and scientific panels for 19 disease sites/tracks. Keynote and featured speakers include: William B. Munier, director of the Center for Quality Improvement and Patient Safety at the Agency for Healthcare Research and Quality; Darrell G. Kirch, MD, president and CEO of the Association of American Medical Colleges; James Cosgrove, PhD, director of the U.S. Government Accountability Office; Otis W. Brawley, MD, chief medical officer of the American Cancer Society; and Peter Friedl, MD, PhD, of St. Radboud University Nijmegen Medical Centre at the University of Nijmegen and MD Anderson Cancer Center.

ABOUT ASTRO

ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes two medical journals, International Journal of Radiation Oncology • Biology • Physics and Practical Radiation Oncology; developed and maintains an extensive patient website, http://www.rtanswers.org; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www.astro.org.

Embargoed until September 23, 2013, 8:30 a.m. ET

2013 American Society for Radiation Oncology (ASTRO) 55th Annual Meeting

News Briefing, Monday, September 23, 2013, 8:30 - 9:15 a.m. Eastern time

Scientific Session: Monday, September 23, 2013, 2:00 – 3:10 pm ET, Georgia World Congress Center

3 RTOG 0841: Two Item Questionnaire Effectively Screens for Depression in Cancer Patients Receiving Radiotherapy

W. Small1, S. Pugh2, L. Wagner1, J. Kirshner3, K. Sidhu4, M. Bury5, A. DeNittis6, T. Alpert3, B. Tran7, D. Bruner8, 1The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, 2Radiation Therapy Oncology Group, Philadelphia, PA, 3Hematology-Oncology Associates of CNY CCOP, Syracuse, NY, 4Southeast Cancer Control Consortium CCOP, Winston-Salem, NC, 5Grand Rapid Clinical Oncology Program, Grand Rapid, MI, 6Maine Line CCOP, Wynnewood, PA, 7Northern Indiana Cancer Research Consortium CCOP, Elkhart, IN, 8Emory University Nell Hodgson Woodruff School of Nursing, Atlanta, GA

Purpose/Objective(s): Depression among patients receiving radiotherapy (RT) for cancer has not been well evaluated. The feasibility of a screening procedure to detect major depression in patients receiving RT was assessed in a multi-institutional setting as well institutional care for psychosocial care services.

Materials/Methods: Depression screening was performed before/within 2 weeks of treatment for first diagnosis of any tumor. The screening evaluations included the 9-item Patient Health Questionnaire (PHQ-9 and with embedded PHQ-2), and the single item National Comprehensive Cancer Network-Distress Thermometer (NCCN-DT). Patients who screened positive and a systematic sample of patients who screened negative were administered the Structured Clinical Interview for DSM IV Disorders (SCID) Mood Disorder modules by telephone. Availability of psychosocial care at participating institutions was also collected.

Results: 463 patients were accrued from 37 sites (95% CCOPs) and 9 were ineligible. 298 (66%) were woman and the most common tumor was breast, 205 (45%). All eligible patients completed the screening questionnaires with 100% item completion; 75 (16%) screened positive for depressive symptoms. PHQ-9 screened 41 (9%) of patients positive (cut-off score ≥ 9) while the PHQ-2 screened 36 (7.9%) positive (cut-off score ≥ 3). The PHQ-2 and PHQ-9 demonstrated good psychometric properties for identifying major depressive episode (ROC area under the curve = 0.84 for both). The NCCN-DT (cut-off score > 4) did not adequately detect depression (AUC=0.64). Most participating sites 25/32 (78% of available data) routinely screen patients at RT facility with 15/29 (51%) screening patients at initial visit. There were mental health services at RT facilities at 23/34 (68%) of sites however most sites 24/36 (67%) had only social workers and few had psychologists 6/36 (17%) or psychiatrists 8/36 (22%).

Conclusions: Screening for depression in RT settings was feasible and acceptable to patients. The PHQ-2 demonstrated psychometric properties equivalent to the PHQ-9 and superior to the NCCN-DT. PHQ-2 should be used to identify patients in need of further assessment and treatment for depression. Most sites had RT facilities equipped for psychosocial care. Supported by RTOG grant U10 CA21661 and CCOP grant U10 CA37422 from the National Cancer Institute (NCI)

Author Disclosure Block: W. Small: None. S. Pugh: None. L. Wagner: None. J. Kirshner: None. K. Sidhu: None. M. Bury: None. A. DeNittis: None. T. Alpert: None. B. Tran: None. D. Bruner: None.

---

[ Print | E-mail |  Share ] [ Close Window ] 

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

HOME   DISCLAIMER   PRIVACY POLICY   TERMS & CONDITIONS   CONTACT US   TOP Copyright ©2013 by AAAS, the science society.